Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

New research shows most patients quit weight loss medications within 12 months. High costs and limited insurance coverage ...

Ozempic, Wegovy and Mounjaro can still be expensive, but pharmacy-produced GLP-1 compounds are becoming much more affordable.

Mounjaro caused the most weight loss. In some respects, the result is not a surprise. Previous separate trials of the drugs, ...

WBZ-TV's Dr. Mallika Marshall reports that drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its ...

Meghan Trainor recently left fans divided after she changed a lyric in one of her most popular songs following ...

Orlistat (sold as Alli) is one effective over-the-counter weight loss aid that is also FDA-approved.

Meghan Trainor has recently sparked backlash after changing the lyrics to one of her most popular songs following weight loss ...

Trump administration has rejected Biden proposal to expand coverage Medicare currently covers Ozempic, Mounjaro solely for diabetes Wegovy, Zepbound not covered for weight ... most popular of the ...

two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top. Injectable GLP-1 receptor agonist ...

Most of the time exclusions don’t harm ... the option of switching to Wegovy or one of three other weight-loss drugs that are not popular because they are not very effective.